At least 16 RCC prognostic models exist that incorporate various clinical, laboratory and radiographic features, with each model examining discrete populations of patients (e.g. post-nephrectomy, prior vascular endothelial growth factor [VEGF] inhibitors, failed immunotherapy, etc.)[4]. This evidence concerns the gene VEGFA and renal cell carcinoma.